Stephen Richards

Dr. Stephen Richards

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Blood
Verified
Journal Article
Open access
PDF file
CPCharles Parker
Charles Parker
MOMitsuhiro Omine
Mitsuhiro Omine
SRStephen Richards
Stephen Richards
JNJun-Ichi Nishimura
Jun-Ichi Nishimura
MBMonica Bessler
Monica Bessler
GSGerard Socié
Gerard Socié

5 February 2004 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
PHPeter Hillmen
Peter Hillmen
CHClaire Hall
Claire Hall
JMJudith C.W. Marsh
Judith C.W. Marsh
MEModupe Elebute
Modupe Elebute
MBMichael P. Bombara
Michael P. Bombara
RRRussell P. Rother
Russell P. Rother
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the clinical efficacy of eculizumab, a humanized antibody that inhibits the activation of terminal complement components, in patients with PNH.

7 August 2008 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ARAndy C. Rawstron
Andy C. Rawstron
FBFiona L. Bennett
Fiona L. Bennett
SOSheila J.M. O'COnnor
Sheila J.M. O'COnnor
MKMarwan Kwok
Marwan Kwok
JFJames A.L. Fenton
James A.L. Fenton
PHPeter Hillmen
Peter Hillmen
A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.

23 June 2011 in Blood
Verified
Journal Article
Closed access
PDF file
RKRichard J. Kelly
Richard J. Kelly
AHAnita Hill
Anita Hill
LALouise M. Arnold
Louise M. Arnold
GBGemma L. Brooksbank
Gemma L. Brooksbank
SRStephen Richards
Stephen Richards
PHPeter Hillmen
Peter Hillmen
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic disorder with increased mortality and morbidity resulting from intravascular hemolysis. Eculizumab, a monoclonal antibody against the complement protein 5, stops the intravascular hemolysis in PNH. We evaluated 79 consecutive patients treated with eculizumab in Leeds between May 2002 and July 2010. The survival of patients treated with eculizumab was not different from age- and sex-matched normal controls (P = .46) but was significantly better than 30 similar patients managed before eculizumab (P = .030). Three patients on eculizumab, all over 50 years old, died of causes unrelated to PNH. Twenty-one patients (27%) had a thrombosis before starting eculizumab (5.6 events per 100 patient-years) compared with 2 thromboses on eculizumab (0.8 events per 100 patient-years; P < .001). Twenty-one patients with no previous thrombosis discontinued warfarin on eculizumab with no thrombotic sequelae. Forty of 61 (66%) patients on eculizumab for more than 12 months achieved transfusion independence. The 12-month mean transfusion requirement reduced from 19.3 units before eculizumab to 5.0 units in the most recent 12 months on eculizumab (P < .001). Eculizumab dramatically alters the natural course of PNH, reducing symptoms and disease complications as well as improving survival to a similar level to that of the general population.

28 April 2010 in Cytometry Part B: Clinical Cytometry
Verified
Journal Article
Closed access
PDF file
MBMichael J. Borowitz
Michael J. Borowitz
FCFiona E. Craig
Fiona E. Craig
JDJoseph A. DiGiuseppe
Joseph A. DiGiuseppe
AIAndrea J. Illingworth
Andrea J. Illingworth
WRWendell Rosse
Wendell Rosse
SRStephen Richards
Stephen Richards

15 September 2007 in Cancer Research
Verified
Journal Article
Closed access
Yasser El-SherbinyYasser El-Sherbiny
Yasser El-Sherbiny
JMJosephine L. Meade
Josephine L. Meade
THTim D. Holmes
Tim D. Holmes
DMDennis McGonagle
Dennis McGonagle
SMSarah L. Mackie
Sarah L. Mackie
GCGraham Cook
Graham Cook
Recent evidence suggests a role for natural killer (NK) cells in the control of multiple myeloma. We show that expression of the NK cell receptor DNAM-1 (CD226) is reduced on CD56dim NK cells from myeloma patients with active disease compared with patients in remission and healthy controls. This suggested that this receptor might play a role in NK-myeloma interactions. The DNAM-1 ligands Nectin-2 (CD112) and the poliovirus receptor (PVR; CD155) were expressed by most patient myeloma samples analyzed. NK killing of patient-derived myelomas expressing PVR and/or Nectin-2 was DNAM-1 dependent, revealing a functional role for DNAM-1 in myeloma cell killing. In myeloma cell lines, cell surface expression of PVR was associated with low levels of NKG2D ligands, whereas cells expressing high levels of NKG2D ligands did not express PVR protein or mRNA. Furthermore, NK cell-mediated killing of myeloma cell lines was dependent on either DNAM-1 or NKG2D but not both molecules. In contrast, the natural cytotoxicity receptor NKp46 was required for the killing of all myeloma cell lines analyzed. Thus, DNAM-1 is important in the NK cell-mediated killing of myeloma cells expressing the cognate ligands. The importance of NKp46, NKG2D, and DNAM-1 in myeloma killing mirrors the differential expression of NK cell ligands by myeloma cells, reflecting immune selection during myeloma disease progression. [Cancer Res 2007;67(18):8444–9]